ASCO 2020: Pembrolizumab plus chemotherapy demonstrated improvement in PFS for patients with metastatic triple-negative breast cancer
Merck has announced positive results from the Phase 3 KEYNOTE-355 trial investigating pembrolizumab in combination with…